237P NeoADAURA: Positron emission tomography response criteria in solid tumors (PERCIST) outcomes following neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CTx) vs placebo (PBO) + CTx in patients (pts) with (w) resectable, EGFRm stage II–IIIB NSCLC